Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASKA Pharmaceutical Holdings CoTSE:4886 -0.83%57 Earnings Yield (Joel Greenblatt) % is 9.77% as of Mar. 2026, which is 37% below its 10-year median of 15.59. GuruFocus rates TSE:4886 with a GF Score™ of 57/100 and a GF Value™ of 円2,412.78 (Modestly Undervalued). Among 1,010 Drug Manufacturers companies, ASKA Pharmaceutical Holdings Co ranks better than 78.81% on this metric.
ASKA Pharmaceutical Holdings Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円73,889 Mil.
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円6,356 Mil. ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 9.77%.
The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TSE:4886'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.81 Med: 15.59 Max: 49.35
Current: 9.17
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of ASKA Pharmaceutical Holdings Co was 49.35%. The lowest was 6.81%. And the median was 15.59%.
TSE:4886's Earnings Yield (Joel Greenblatt) % is ranked better than 78.81% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 2.995
vs TSE:4886: 9.17
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ASKA Pharmaceutical Holdings Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co Earnings Yield (Joel Greenblatt) % Chart
TSE:4886 vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASKA Pharmaceutical Holdings Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % falls into.
ASKA Pharmaceutical Holdings Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ASKA Pharmaceutical Holdings Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,356 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 9.77% mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Earnings Yield (Joel Greenblatt) % of 9.77% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. This is 37% below median its historical median of 15.59. Over the past decade, ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % has ranged from 6.81 to 49.35. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #214 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % too high?
ASKA Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % of 9.77% is 37% below median its 10-year median of 15.59. Over the past 10 years, this metric has ranged from a low of 6.81 to a high of 49.35. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.00. ASKA Pharmaceutical Holdings Co's value of 9.77% is 226.2% above this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #214 out of 1010 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #214 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places ASKA Pharmaceutical Holdings Co in the top 21% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.00. ASKA Pharmaceutical Holdings Co's value of 9.77% is 226.2% above this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own Earnings Yield (Joel Greenblatt) % has ranged from 6.81 to 49.35 over the past decade. While the company's 10-year median is 15.59 vs. the industry median of 3.00, ASKA Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.00, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % of 9.77% is 226.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % is 9.77%, which is 37% below median its own 10-year median of 15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,412.78, compared to a current price of 円2,040.00 — trading 15.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 9.77%, which is 37% below median its 10-year median of 15.59 and 226.2% above the Drug Manufacturers industry median of 3.00. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Earnings Yield (Joel Greenblatt) % is 9.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,040.00 is trading 15.5% below its estimated GF Value™ of 円2,412.78.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for TSE:4886:
Earnings Yield (Joel Greenblatt) %: 9.77% (37% below median its 10-year median of 15.59)
GF Value™: 円2,412.78 vs. price of 円2,040.00 (15.5% below fair value)
Industry Position: 226.2% above the Drug Manufacturers median (#214 of 1010)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
57GF Score
Get the complete analysis for TSE:4886
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
